newsfilter
← Latest News
GlobeNewswire·

Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results

Presented three abstracts at American Society of Gene & Cell Therapy ("ASGCT") demonstrating early proof-of-concept data across multiple gene editing technologies Well capitalized with $205.0 million in cash, cash